Equities

Fusion Antibodies PLC

FAB:LSE

Fusion Antibodies PLC

Actions
Health CareHealth Care Equipment & Services
  • Price (GBX)113.00
  • Today's Change-2.00 / -1.74%
  • Shares traded98.34k
  • 1 Year change50.67%
  • Beta--
Data delayed at least 20 minutes, as of Nov 23 2020 16:16 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Fusion Antibodies PLC, formerly Fusion Antibodies, Ltd., is a United Kingdom-based cancer therapeutics developer. The Company develops and commercializes antibody-based therapeutics for cancer. The Company develops a range of antibody engineering services based around monoclonal antibodies. It focuses in the expression and purification of recombinant proteins and chimeric antibodies for the research, diagnostic and therapeutic markets. Its technology generates target specific antibodies from protein antigens. The Company's therapeutic and diagnostic research and development are offered as a service to pharmaceutical, biopharmaceutical and academic researchers.

  • Revenue in GBP (TTM)3.90m
  • Net income in GBP-697.00k
  • Incorporated2000
  • Employees47.00
  • Location
    Fusion Antibodies PLCSpringbank Industrial Estate1 Springbank RoadBELFAST BT17 0QLUnited KingdomGBR
  • Phone+44 289 043 2800
  • Fax+44 289 002 0446
  • Websitehttps://fusionantibodies.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Midatech Pharma PLC390.00k-22.14m17.03m65.00--2.33--43.67-0.8572-0.90110.0160.11580.0192--0.12526,000.00-109.24-20.71-148.64-24.26-----5,676.67-753.63----0.4355---65.2233.8311.86---20.90--
Provexis plc347.94k-406.23k17.60m4.00--21.49--50.59-0.0002-0.00020.00020.00040.74761.283.49---91.21-133.18-52.06-68.3289.72---122.00-185.863.06--0.00--7.9955.5420.82------
Skinbiotherapeutics PLC0.00-1.44m24.94m4.00--6.76-----0.0113-0.01130.000.02370.00-------45.95---48.13--------------0.00-------35.96------
MiLOC Group Limited2.31m-3.33m25.26m6.00------10.94-0.0406-0.04060.0282-0.07171.412.8213.54---211.42-140.25----34.1141.02-149.57-218.440.0898-37.67----44.650.9406-7.05--25.76--
Tissue Regenix Group PLC13.05m-5.26m28.31m99.00--0.7634--2.17-0.0041-0.00410.00980.00530.31491.544.60131,808.10-13.09-31.17-14.33-34.5146.8249.52-41.57-137.514.00-11.830.0778--12.17164.8614.82--41.69--
ReNeuron Group Plc6.07m-11.41m30.92m61.00--2.34--5.10-0.3587-0.35870.19070.41540.2338--7.9399,426.23-43.99-31.41-60.00-35.82-----188.16-1,128.08----0.0619--12,277.55189.1620.46--14.30--
Destiny Pharma PLC0.00-5.04m31.72m16.00--5.52-----0.1145-0.11450.000.12240.00----0.00-60.16-39.10-64.38-41.32------------0.00------8.88--92.12--
Fusion Antibodies PLC3.90m-697.00k31.80m47.00--5.74--8.16-0.0316-0.03160.17630.21780.63427.294.8882,872.34-11.35-6.71-13.28-7.7545.4948.38-17.89-11.412.49-75.640.0732--78.5233.7744.87--57.63--
Futura Medical plc.31.78k-5.52m35.00m13.00--16.52--1,101.38-0.0262-0.02620.00010.00860.0058--10.152,444.62-99.86-58.40-168.03-68.33-----17,369.76-4,623.323.17--0.00-----6.27-51.67--33.26--
Hemogenyx Pharmaceuticals PLC0.00-1.58m40.11m7.00--20.49-----0.0042-0.00420.000.00450.00----0.00-58.29---61.72-------------58.810.4731------6.07------
Science in Sport PLC50.57m-5.62m41.88m142.00--0.8424--0.8281-0.0458-0.04580.41210.3680.8494.285.09---9.43-13.25-11.15-15.4843.9151.63-11.11-17.631.57-232.000.0233--137.23--4.37------
OptiBiotix Health PLC1.34m-1.51m45.73m10.00--8.20--34.10-0.0176-0.01760.01560.06340.18146.425.68134,088.00-20.38-14.81-21.36-15.5946.8264.52-112.34-266.914.98--0.1178--44.84---10.32--252.06--
Data as of Nov 23 2020. Currency figures normalised to Fusion Antibodies PLC's reporting currency: UK Pound GBX

Institutional shareholders

15.78%Per cent of shares held by top holders
HolderShares% Held
Octopus Investments Ltd.as of 14 Aug 20201.53m6.00%
Canaccord Genuity Wealth Ltd.as of 21 Sep 20201.27m4.99%
Unicorn Asset Management Ltd.as of 14 Aug 20201.22m4.79%
Data from 31 Jul 2020 - 31 Oct 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.